Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NCCAM

This article was originally published in The Tan Sheet

Executive Summary

Botanical-drug interaction grants to receive $4.3 mil. in FY 2001 funding, the NIH center announces in a request for applications released Aug. 7. NCCAM plans to support 10 Exploratory/Developmental Research (R21) grants and five investigator-initiated (R01) awards. Mechanistic, case control and Phase I and II trials will be considered. Letters of intent are due Nov. 10 and applications must be submitted by Jan. 12, 2001; the anticipated award date is August 2001. NCCAM's advisory council reviewed and endorsed the program concept in May (1"The Tan Sheet" May 15, p. 15)

You may also be interested in...



Botanical/Drug Interactions To Be Studied By NCCAM

A project concept calling for the study of botanical/ drug interactions in animal models through Phase I/II clinical studies was approved by the National Center for Complementary & Alternative Medicine's advisory council at a May 8 meeting in Rockville, Md.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS091639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel